ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.557,27
-0,48%
S&P 500
5.346,99
-0,11%
Dow Jones
38.798,99
-0,22%
Euro vs US Dollar
1,0804
-0,12%
Bitcoin
69.423,38
0,13%
Registration Strip Icon for monitor Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Roivant Sciences Ltd (ROIV)

  7. Roivant Sciences Ltd (ROIV) News

ROIV

Roivant Sciences (ROIV)

Roivant Sciences Ltd
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:ROIV
DatumZeitQuelleÜberschriftSymbolFirma
31/05/202403h00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ROIVRoivant Sciences Ltd
30/05/202422h46Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:ROIVRoivant Sciences Ltd
30/05/202413h45Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ROIVRoivant Sciences Ltd
30/05/202413h15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ROIVRoivant Sciences Ltd
30/05/202413h00GlobeNewswire Inc.Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024, and Provides Business UpdateNASDAQ:ROIVRoivant Sciences Ltd
23/05/202403h01Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ROIVRoivant Sciences Ltd
23/05/202403h01Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ROIVRoivant Sciences Ltd
23/05/202403h01Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ROIVRoivant Sciences Ltd
16/05/202422h05GlobeNewswire Inc.Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024, and Provide Business Update on Thursday, May 30, 2024NASDAQ:ROIVRoivant Sciences Ltd
02/04/202413h00GlobeNewswire Inc.Roivant Announces Positive NEPTUNE Study Results for Brepocitinib in NIU, as well as Board Authorization for up to $1.5 Billion Share Repurchase Program, Including Repurchase of Entire Sumitomo Pharma Stake for $648 MillionNASDAQ:ROIVRoivant Sciences Ltd
26/03/202423h22PR Newswire (US)Roivant Sciences Set to Join S&P MidCap 400; Sunrun to Join S&P SmallCap 600NASDAQ:ROIVRoivant Sciences Ltd
13/02/202413h00GlobeNewswire Inc.Roivant Reports Financial Results for the Third Quarter Ended December 31, 2023, and Provides Business UpdateNASDAQ:ROIVRoivant Sciences Ltd
30/01/202422h05GlobeNewswire Inc.Roivant to Report Financial Results for the Third Quarter Ended December 31, 2023, and Provide Business Update on Tuesday, February 13, 2024NASDAQ:ROIVRoivant Sciences Ltd
20/12/202322h30GlobeNewswire Inc.Roivant Reports Positive Initial Phase 2 Results for Batoclimab in Graves’ DiseaseNASDAQ:ROIVRoivant Sciences Ltd
14/12/202315h00GlobeNewswire Inc.Roche Completes Acquisition of Telavant from Roivant, Including Rights to Novel TL1A Directed Antibody (RVT-3101) for the Treatment of Inflammatory Bowel DiseaseNASDAQ:ROIVRoivant Sciences Ltd
28/11/202313h00GlobeNewswire Inc.Roivant Announces Positive IMVT-1402 Initial 600 mg MAD Results that Confirm Best-in-Class PotentialNASDAQ:ROIVRoivant Sciences Ltd
27/11/202314h00GlobeNewswire Inc.Roivant and Priovant Announce Results from Phase 2 Study of Oral Brepocitinib in Systemic Lupus ErythematosusNASDAQ:ROIVRoivant Sciences Ltd
13/11/202313h00GlobeNewswire Inc.Roivant Reports Financial Results for the Second Quarter Ended September 30, 2023, and Provides Business UpdateNASDAQ:ROIVRoivant Sciences Ltd
10/11/202314h00GlobeNewswire Inc.Roivant Announces Appointment of Mayukh Sukhatme to Its Board of DirectorsNASDAQ:ROIVRoivant Sciences Ltd
30/10/202322h30GlobeNewswire Inc.Roivant to Report Financial Results for the Second Quarter Ended September 30, 2023, and Provide Business Update on Monday, November 13, 2023NASDAQ:ROIVRoivant Sciences Ltd
23/10/202321h41Dow Jones NewsTrending: Roche to Buy Telavant From Roivant and PfizerNASDAQ:ROIVRoivant Sciences Ltd
23/10/202313h18IH Market NewsMonday’s Wall Street Highlights: Philips, Chevron, Textainer, Okta, Roivant, and moreNASDAQ:ROIVRoivant Sciences Ltd
23/10/202310h16Dow Jones NewsRoche to Buy Telavant From Roivant, Pfizer in Deal Worth Up to $7.25 Billion -- UpdateNASDAQ:ROIVRoivant Sciences Ltd
23/10/202307h50Dow Jones NewsRoche to Buy Telavant From Roivant Sciences and Pfizer in $7.25 Billion DealNASDAQ:ROIVRoivant Sciences Ltd
23/10/202307h00GlobeNewswire Inc.Roche Enters Into a Definitive Agreement to Acquire Telavant Including Rights to Novel TL1A Directed Antibody (RVT-3101) for the Treatment of Inflammatory Bowel Disease From RoivantNASDAQ:ROIVRoivant Sciences Ltd
13/10/202314h00GlobeNewswire Inc.Covant Therapeutics Appoints Vincent Hennemand as Chief Executive OfficerNASDAQ:ROIVRoivant Sciences Ltd
26/09/202312h00GlobeNewswire Inc.Roivant Announces Positive Initial IMVT-1402 Phase 1 SAD and 300 mg Subcutaneous MAD ResultsNASDAQ:ROIVRoivant Sciences Ltd
11/09/202314h00GlobeNewswire Inc.Roivant Announces Completion of Redemption of its Outstanding WarrantsNASDAQ:ROIVRoivant Sciences Ltd
17/08/202322h05GlobeNewswire Inc.Roivant Announces Redemption Fair Market Value in Connection with Redemption of its Outstanding WarrantsNASDAQ:ROIVRoivant Sciences Ltd
14/08/202313h00GlobeNewswire Inc.Roivant Reports Financial Results for the First Quarter Ended June 30, 2023, and Provides Business UpdateNASDAQ:ROIVRoivant Sciences Ltd
 Showing the most relevant articles for your search:NASDAQ:ROIV

Kürzlich von Ihnen besucht

LSE
BL27
Citi Fun 25
EU
ALINK
21Shares
TSX
ZAUT
BMO MSCI Tech & Industri...
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten